2. Search Result
Search Result
Results for "

intestinal bowel disorder

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-161440
    SIK-IN-1

    		AMPK Inflammation/Immunology
    SIK-IN-1 (Compound 53) is an inhibitor for salt-inducible kinase (SIK), which inhibits SKI1, SIK2 and SIK3 with IC50s of 0.1, 0.4 and 1.5 nM, respectively. SIK-IN-1 inhibits the release of TNFa with IC50 of 0.5 nM, stimulates the LPS (HY-D1056) -induced IL-10 release with EC50 of 4 nM in human macrophages .
    SIK-IN-1
  • HY-161441
    SIK-IN-2

    		AMPK Inflammation/Immunology
    SIK-IN-2 (Compound 45) is an inhibitor for salt-inducible kinase (SIK), which inhibits SKI1, SIK2 and SIK3 with IC50s of 0.1, 0.2 and 0.4 nM, respectively. SIK-IN-2 inhibits the release of TNFa with IC50 of 0.5 nM, stimulates the LPS (HY-D1056) -induced IL-10 release with EC50 of 2 nM in human macrophages .
    SIK-IN-2
  • HY-161442
    SIK-IN-3

    		AMPK Inflammation/Immunology
    SIK-IN-3 (Compound 6B) is an inhibitor for salt-inducible kinase (SIK), which inhibits SKI1, SIK2 and SIK3 with IC50s of 0.1, 0.3 and 0.8 nM, respectively. SIK-IN-1 inhibits the release of TNFa with IC50 of 0.6 nM, stimulates the LPS (HY-D1056) -induced IL-10 release with EC50 of 3 nM in human macrophages .
    SIK-IN-3
  • HY-101225
    8 Hydroxy PIPAT oxalate

    		Histamine Receptor Inflammation/Immunology
    8 Hydroxy PIPAT oxalate is a selective 5-HT1A receptor agonist that promotes the release of histamine from enteric mast cells. 8 Hydroxy PIPAT oxalate activates serotonergic signaling pathways, leading to the degranulation of mast cells in both guinea pig and human intestinal preparations. 8 Hydroxy PIPAT oxalate enhances the spontaneous release of histamine, which may contribute to the regulation of gastrointestinal functions. 8 Hydroxy PIPAT oxalate has potential implications for understanding and treating functional gastrointestinal disorders such as irritable bowel syndrome.
    8 Hydroxy PIPAT oxalate
  • HY-15026
    ATB 429

    		Endogenous Metabolite Inflammation/Immunology
    ATB-429, a novel H2S-releasing derivative of mesalamine, demonstrates significant anti-nociceptive and anti-inflammatory effects in models of irritable bowel syndrome (IBS). By releasing hydrogen sulfide (H2S), ATB-429 modulates colorectal distension-induced hypersensitivity in both healthy and postcolitic rats. It attenuates abdominal withdrawal responses and suppresses spinal c-Fos mRNA expression, indicating its potential to alleviate pain associated with gastrointestinal inflammation. Moreover, ATB-429 down-regulates colonic cyclooxygenase-2 and interleukin-1β mRNA expression, effects not observed with mesalamine alone. The mechanism involves ATP-sensitive K+ (KATP) channels, as evidenced by reversal of ATB-429's effects with glibenclamide. These findings suggest ATB-429 could offer therapeutic benefits for managing painful intestinal disorders linked to inflammation .
    ATB 429

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: